Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - minoxidil, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; maize starch; colloidal anhydrous silica - indications as at 1 january 1991 : indicated as adjunctive therapy in adults with severe refractory hypertension which has failed to respond to extensive multiple therapy. when used in combination with an accompanying diuretic and beta-blocker, minoxidil (loniten) has been shown to reverse encephalopathy and retinopathy in severe hypertensives.

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

Israel - English - Ministry of Health

bayer israel ltd - rivaroxaban - film coated tablets - rivaroxaban 10 mg - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.prevention of recurrent deep vein thrombosis (dvt) and pulmonary embolism (pe), adults (following completion of at least 6 months therapy for dvt or pe).

European Union - English - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5.1),visual impairment due to diabetic macular oedema (dme) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.1).

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

bayer yakuhin, ltd. - aflibercept (genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

santen pharmaceutical co.,ltd. - aflibercept (genetical recombination) - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

novartis pharma k.k. - ranibizumab(genetical recombination) - injection

European Union - English - EMA (European Medicines Agency)

allergan pharmaceuticals ireland - bimatoprost, timolol - glaucoma, open-angle, ocular hypertension - ophthalmologicals, - reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.